Emmanuel Hriso, MD
Psychiatry · Woodbridge, NJNPI 1942217328
Payments from drug & device makers
Across 566 payments — averaging $14.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$713
- Takeda Pharmaceuticals U.S.A., Inc.$617
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$592
- Teva Pharmaceuticals USA, Inc.$582
- Alkermes, Inc.$565
- plus $3K from 24 others
What the payments were for
- Food & beverage$8,03496%
- Education$3514%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 184 | $2,317 |
| Otsuka America Pharmaceutical, Inc. | 38 | $713 |
| Takeda Pharmaceuticals U.S.A., Inc. | 53 | $617 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 40 | $592 |
| Teva Pharmaceuticals USA, Inc. | 22 | $582 |
| Alkermes, Inc. | 30 | $565 |
| Lundbeck LLC | 30 | $460 |
| Bausch Health US, LLC | 31 | $420 |
| Sunovion Pharmaceuticals Inc. | 21 | $317 |
| Vanda Pharmaceuticals Inc. | 19 | $259 |
| Idorsia Pharmaceuticals US Inc | 5 | $176 |
| Johnson & Johnson | 10 | $174 |
| Axsome Therapeutics, Inc. | 11 | $169 |
| Tris Pharma Inc | 10 | $156 |
| Avanir Pharmaceuticals, Inc. | 11 | $148 |
| Merck | 8 | $116 |
| Eisai Inc. | 8 | $112 |
| Corium, LLC | 6 | $81 |
| Jazz Pharmaceuticals Inc. | 6 | $80 |
| Neurocrine Biosciences, Inc. | 4 | $54 |
| Supernus Pharmaceuticals, Inc. | 3 | $43 |
| Arbor Pharmaceuticals, Inc. | 3 | $43 |
| Collegium Pharmaceutical, Inc. | 2 | $31 |
| Adlon Therapeutics L.p. | 2 | $30 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Noven Therapeutics, LLC | 2 | $28 |
| Shire North American Group Inc | 2 | $26 |
| Almatica Pharma LLC | 1 | $19 |
| Noven Pharmaceuticals, Inc. | 1 | $16 |
| Neos Therapeutics, LP | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,385 in reported general payments places this provider in the 90th percentile of 1,119 psychiatry providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 89 | $138,356 |
| RexultiBrexpiprazole | 19 | $59,784 |
| NuedextaDextromethorphan Hbr/Quinidine | 35 | $52,389 |
| Effexor XrVenlafaxine Hcl | 15 | $29,452 |
| TrintellixVortioxetine Hydrobromide | 25 | $23,259 |
| BelsomraSuvorexant | 41 | $19,779 |
| LybalviOlanzapine/Samidorphan Malate | 11 | $17,033 |
| CymbaltaDuloxetine Hcl | 21 | $14,720 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 62 | $10,706 |
| Aripiprazole | 203 | $9,763 |
| ProzacFluoxetine Hcl | 12 | $9,392 |
| Lisdexamfetamine Dimesylate | 30 | $7,425 |
| Bupropion XlBupropion Hcl | 285 | $7,303 |
| Quetiapine Fumarate | 322 | $6,571 |
| AuvelityDextromethorphan Hbr/Bupropion | 12 | $6,523 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $2,317 | $138,35689 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $713 | $59,78419 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $148 | $52,38935 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $617 | $29,08440 claims |
| MerckBelsomra | $116 | $19,77941 claims |
| Alkermes, Inc.Lybalvi | $565 | $17,03311 claims |
| Axsome Therapeutics, Inc.Auvelity | $169 | $6,52312 claims |
| Corium, LLCAzstarys | $81 | $5,33513 claims |
| Almatica Pharma LLCSertraline Hcl | $19 | $2,362267 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,119 psychiatry providers in New Jersey.
Other psychiatry in Woodbridge
- Leon RosenbergCherry Hill$6.4M
- Steven GlassClementon$3.9M
- Judith JosephPaterson$3.8M
- Jeffrey ApterPrinceton$1.7M
- Roberta BallCherry Hill$741K
- Marc CantillonLivingston$524K
- Sanjay VarmaPrinceton$479K
- Manuel SanchezNewark$474K
- Robert BransfieldRed Bank$415K
- Erika ConcepcionLong Branch$354K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.